Making the Most of the EU's Regulatory Resources
This article was originally published in SRA
The European Generic medicines Association's 8th regulatory and scientific affairs conference took place on 29-30 January in Amsterdam. The event covered a number of issues affecting the generic medicines sector, such as making the most efficient use of existing resources by national competent authorities in order to achieve an efficient regulatory system in Europe, improvements to the variations regulations that will affect both authorities and industry, and the implementation of electronic submissions. It also discussed current experience and advice on how to update the patient information leaflet and the summary of product characteristics of generic medicines to reflect changes to the reference product, and touched on the European Commission's inquiry into competition in the EU pharmaceutical sector.
You may also be interested in...
DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker